Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel Eight-Color Flow Cytometry Approach

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00082240" target="_blank" >RIV/00216224:14740/15:00082240 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063173

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21210/epdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21210/epdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cytob.21210" target="_blank" >10.1002/cytob.21210</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel Eight-Color Flow Cytometry Approach

Popis výsledku v původním jazyce

Backround: Minimal residual disease (MRD) detection is an essential tool for therapy response assessment in a considerable number of hematooncologic disorders including mantle cell lymphoma (MCL). Flow cytometry (FCM) ranks among the most effective approaches which allow rapid sample processing and compete successfully with highly sensitive molecular methods like polymerase chain reaction (PCR). Since FCM is ordinarily applied to detect MRD in B-lineage diseases like chronic lymphocytic leukemia (CLL),a similar method could be used in MCL. We decided to test our novel 8-color FCM approach in MCL MRD detection. Methods: Employing an 8-color FCM protocol designed by us, the expression of 24 selected surface antigens in a cohort of 30 patients with newlydiagnosed leukemic MCL and 20 normal controls were compared to one another to establish markers that can reliably distinguish normal B lymphocytes from the MCL population.

Název v anglickém jazyce

Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel Eight-Color Flow Cytometry Approach

Popis výsledku anglicky

Backround: Minimal residual disease (MRD) detection is an essential tool for therapy response assessment in a considerable number of hematooncologic disorders including mantle cell lymphoma (MCL). Flow cytometry (FCM) ranks among the most effective approaches which allow rapid sample processing and compete successfully with highly sensitive molecular methods like polymerase chain reaction (PCR). Since FCM is ordinarily applied to detect MRD in B-lineage diseases like chronic lymphocytic leukemia (CLL),a similar method could be used in MCL. We decided to test our novel 8-color FCM approach in MCL MRD detection. Methods: Employing an 8-color FCM protocol designed by us, the expression of 24 selected surface antigens in a cohort of 30 patients with newlydiagnosed leukemic MCL and 20 normal controls were compared to one another to establish markers that can reliably distinguish normal B lymphocytes from the MCL population.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cytometry Part B: Clinical Cytometry

ISSN

1552-4949

e-ISSN

—

Svazek periodika

88

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

92-100

Kód UT WoS článku

000350302000003

EID výsledku v databázi Scopus

—